The effect of propranolol on gastrointestinal motility and permeability in patients with cirrhosis and significant portal hypertension
Open Access
- 21 November 2024
- journal article
- research article
- Published by Springer Nature in BMC Gastroenterology
- Vol. 24 (1) , 1-11
Abstract
Patients with cirrhosis and portal hypertension may have alterations in intestinal barrier resulting in increased susceptibility for infections. We investigated the effect of propranolol in gastrointestinal motility, permeability and bacterial overgrowth in cirrhosis. Patients with cirrhosis and esophageal varices were studied before and after a build-up dose of propranolol according to standard guidelines. Serum TNF-a, IL-6, IL-1b, LPS and bacterial DNA were measured before and during propranolol therapy. Oro-caecal transit time (OCTT) and bacterial overgrowth (BO) have been evaluated with H2 breath testing. Intestinal paracellular (IP), cellular passive non-carrier (ICNC), cellular passive carrier-mediated (ICCM), and gastric permeability (GP) were evaluated by measurement of lactulose, mannitol, D-xylose and sucrose respectively in urine, with high performance liquid chromatography (HPLC). 35 patients with cirrhosis and portal hypertension with median age was 59.6 years (range 42–86) were included in the study. Twenty one had viral hepatitis and 25 were classified as having advanced cirrhosis (Child-Pugh B: 14 or C: 11). Median dose of administrated propranolol was 40 mg/day. After 7 days propranolol treatment BO was resolved in 15 out of 16 patients (93.7%, p = 0.0001) and OCTT was reduced significantly from 180 min to 139 min (SD 58.5, difference − 4 1 min, p = 0.0001). Serum IL-6 levels were reduced in 21/35 (60%) patients from 41.1 to 19 pg/ml (p = 0.01), TNF-a in 10/35 (28.5%) patients from 10.7 to 5.6 pg/ml (p = 0.007) and LPS in 20/35 (57%) from 7.1 to 5.2 mg/L (p = 0.1). No bacterial DNA was detected in serum of all patients either baseline or under propranolol treatment. IP was significantly reduced (0.2 to 0.16, p = 0.04) whereas ICNC (p = 0.9), ICCM (p = 0.4) and GP (p = 0.7) were not affected significantly. Intestinal Permeability (PI) index (Lactulose to Mannitol ratio) was significantly reduced (0.027 to 0.02, p = 0.03). In patients with cirrhosis and portal hypertension, propranolol use is associated with reduction in BO, increase in intestinal motility and amelioration in intestinal permeability. Moreover IL-6 and LPS levels are being decreased in the majority of patients under propranolol.Keywords
All Related Versions
Funding Information
- The study was supported by an unrestricted grant from Hellenic Association for the Study of the Liver
This publication has 55 references indexed in Scilit:
- Influence of the Substrate on the Reproducibility of the Hydrogen Breath Test to Measure the Orocecal Transit TimeDigestion, 1998
- Small Intestine Dysmotility and Bacterial Overgrowth in Cirrhotic Patients With Spontaneous Bacterial PeritonitisHepatology, 1998
- Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhageHepatology, 1998
- Gastric emptying and orocecal transit in portal hypertension and end-stage chronic liver diseaseLiver Transplantation and Surgery, 1997
- The lactulose breath hydrogen test and small intestinal bacterial overgrowth.1996
- Small bowel bacterial overgrowth in patients with alcoholic cirrhosisDigestive Diseases and Sciences, 1995
- The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study.1995
- Lactulose hydrogen breath test in orocecal transit assessmentDigestive Diseases and Sciences, 1994
- Intestinal carbohydrate absorption and permeability at high altitude (5,730 m)Journal of Applied Physiology, 1994
- Reduced gastric mucosal blood flow in patients with portal-hypertensive gastropathy.1993